News
The FDA has approved Emrelis for the treatment of adult patients with locally advanced or metastatic NSCLC with high c-Met protein overexpression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback